<DOC>
	<DOC>NCT00847899</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.</brief_summary>
	<brief_title>Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>mild to moderate hypertension naive to antihypertensive medication or on two or less antihypertensive medications impaired glucose tolerance mild obesity Diagnosis of Type 1 or Type 2 diabetes History of severe heart failure AST, ALT levels more than twice the normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>hypertension</keyword>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>s-EH enzyme inhibition</keyword>
	<keyword>pre-diabetes</keyword>
</DOC>